We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix Study.
- Authors
Hirayama, Daisuke; Motoya, Satoshi; Ashida, Toshifumi; Ando, Katsuyoshi; Fujiya, Mikihiro; Ito, Takahiro; Furukawa, Shigeru; Maemoto, Atsuo; Katsurada, Takehiko; Hinotsu, Shiro; Sato, Noriko; Mizuno, Naomi; Ikawa, Yoshiko; Nakase, Hiroshi
- Abstract
Introduction: There have been limited reports on the clinical efficacy of golimumab (GLM) in Japanese patients with ulcerative colitis (UC) in real clinical practice. This study aimed to explore the real-life effectiveness and factors associated with response to GLM in Japanese patients with UC. Methods: This observational, retrospective, multicenter study was conducted in hospitals with expertise in inflammatory bowel disease treatment. Sixty-three patients treated with GLM and active UC were included in the analysis. Clinical remission (CR) (partial Mayo (pMayo) score ≤2) in the induction and maintenance phases after GLM treatment and associated factors were evaluated. Results: The proportion of patients achieving CR in the induction and maintenance phases was 41.3% (26/63) and 46.0% (29/63, the last observation carried forward method was used for patients who discontinued treatment for reasons other than inadequate response), respectively. The median pMayo score was 5 (interquartile range (IQR): 4–6) at baseline, 3 (IQR: 1–5) in the induction phase, and 1 (IQR: 0–3) in the maintenance phase. Hemoglobin, platelet, and C-reactive protein levels changed, consistent with the pMayo score. Multivariate logistic analysis revealed that biologic-naive status was an independent factor associated with CR in the induction (p = 0.0200) and maintenance (p = 0.0459) phases, and a disease duration of >60 months until GLM initiation was associated with CR in the induction phase (p = 0.0427). Conclusions: The effectiveness of GLM in daily clinical practice has been confirmed in Japanese patients with active UC. Biologic-naive patients responded more to GLM in the induction and maintenance phases, and patients with disease duration of >60 months until initiation of GLM were more responsive in the induction phase.
- Subjects
ULCERATIVE colitis; JAPANESE people; INFLAMMATORY bowel diseases; GOLIMUMAB; DISEASE remission
- Publication
Inflammatory Intestinal Diseases, 2023, Vol 8, Issue 3, p115
- ISSN
2296-9403
- Publication type
Article
- DOI
10.1159/000533871